Alexandros Polymeris, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 39 | 2025 | 9755 | 1.910 |
Why?
|
Atrial Fibrillation | 21 | 2025 | 5182 | 1.690 |
Why?
|
Brain Ischemia | 19 | 2023 | 3007 | 1.480 |
Why?
|
Anticoagulants | 25 | 2025 | 4854 | 1.410 |
Why?
|
Cerebral Hemorrhage | 12 | 2024 | 2655 | 0.740 |
Why?
|
Antifibrinolytic Agents | 2 | 2023 | 289 | 0.720 |
Why?
|
Tranexamic Acid | 1 | 2023 | 174 | 0.720 |
Why?
|
Administration, Oral | 14 | 2025 | 4030 | 0.720 |
Why?
|
Hemostatics | 1 | 2023 | 246 | 0.710 |
Why?
|
Thrombolytic Therapy | 7 | 2022 | 2055 | 0.660 |
Why?
|
Thromboembolism | 2 | 2024 | 1003 | 0.580 |
Why?
|
Ischemic Attack, Transient | 5 | 2022 | 877 | 0.540 |
Why?
|
Intracranial Hemorrhages | 9 | 2023 | 810 | 0.520 |
Why?
|
Medication Adherence | 5 | 2024 | 2187 | 0.510 |
Why?
|
Cerebrovascular Disorders | 2 | 2019 | 1484 | 0.460 |
Why?
|
Spastic Paraplegia, Hereditary | 1 | 2016 | 171 | 0.440 |
Why?
|
Vitamin K | 5 | 2024 | 314 | 0.410 |
Why?
|
Vertebral Artery Dissection | 2 | 2024 | 48 | 0.400 |
Why?
|
Adenosine Triphosphatases | 1 | 2016 | 842 | 0.390 |
Why?
|
GTP-Binding Proteins | 1 | 2016 | 948 | 0.390 |
Why?
|
Secondary Prevention | 4 | 2024 | 1474 | 0.370 |
Why?
|
Aged, 80 and over | 27 | 2025 | 59598 | 0.360 |
Why?
|
Fibrinolytic Agents | 8 | 2024 | 2080 | 0.320 |
Why?
|
Recovery of Function | 4 | 2024 | 2981 | 0.270 |
Why?
|
Switzerland | 6 | 2024 | 323 | 0.270 |
Why?
|
Seizures | 1 | 2019 | 2998 | 0.260 |
Why?
|
Hemorrhage | 6 | 2025 | 3467 | 0.250 |
Why?
|
Cerebral Amyloid Angiopathy | 2 | 2023 | 887 | 0.250 |
Why?
|
Hematoma | 3 | 2024 | 766 | 0.230 |
Why?
|
Aged | 31 | 2025 | 171446 | 0.200 |
Why?
|
Disability Evaluation | 2 | 2022 | 1835 | 0.190 |
Why?
|
Leukopenia | 1 | 2022 | 212 | 0.190 |
Why?
|
Siderosis | 1 | 2022 | 100 | 0.190 |
Why?
|
Male | 35 | 2025 | 364641 | 0.190 |
Why?
|
Carotid Artery, Internal, Dissection | 1 | 2021 | 39 | 0.180 |
Why?
|
Aspirin | 2 | 2024 | 3135 | 0.180 |
Why?
|
Muscle Tonus | 1 | 2020 | 82 | 0.180 |
Why?
|
Hepatolenticular Degeneration | 1 | 2020 | 73 | 0.170 |
Why?
|
Female | 34 | 2025 | 397113 | 0.170 |
Why?
|
Cerebral Arterial Diseases | 1 | 2019 | 82 | 0.160 |
Why?
|
Humans | 54 | 2025 | 767991 | 0.160 |
Why?
|
Membrane Proteins | 1 | 2016 | 7876 | 0.160 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2017 | 5717 | 0.160 |
Why?
|
Treatment Outcome | 15 | 2025 | 65364 | 0.160 |
Why?
|
Hyponatremia | 1 | 2022 | 279 | 0.160 |
Why?
|
Registries | 5 | 2024 | 8377 | 0.160 |
Why?
|
Gait Disorders, Neurologic | 1 | 2020 | 243 | 0.150 |
Why?
|
Prospective Studies | 15 | 2024 | 54924 | 0.150 |
Why?
|
Thrombocytopenia | 2 | 2022 | 1179 | 0.130 |
Why?
|
Dimethyl Sulfoxide | 1 | 2017 | 250 | 0.130 |
Why?
|
Cryoprotective Agents | 1 | 2017 | 128 | 0.130 |
Why?
|
Atherosclerosis | 2 | 2023 | 3433 | 0.130 |
Why?
|
Sodium | 1 | 2022 | 1597 | 0.130 |
Why?
|
Greece | 1 | 2016 | 340 | 0.130 |
Why?
|
Self Administration | 1 | 2016 | 386 | 0.120 |
Why?
|
Middle Aged | 21 | 2025 | 223422 | 0.120 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 18062 | 0.110 |
Why?
|
Recombinant Proteins | 1 | 2024 | 6515 | 0.110 |
Why?
|
Deglutition Disorders | 1 | 2019 | 640 | 0.110 |
Why?
|
Enteral Nutrition | 1 | 2019 | 802 | 0.100 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2022 | 2764 | 0.100 |
Why?
|
Metformin | 1 | 2020 | 909 | 0.100 |
Why?
|
Cryopreservation | 1 | 2017 | 733 | 0.100 |
Why?
|
Cohort Studies | 10 | 2024 | 41749 | 0.100 |
Why?
|
Mutation | 1 | 2016 | 30211 | 0.090 |
Why?
|
Risk Factors | 11 | 2024 | 74936 | 0.090 |
Why?
|
Tissue Plasminogen Activator | 1 | 2017 | 1165 | 0.090 |
Why?
|
Drug Monitoring | 1 | 2017 | 964 | 0.090 |
Why?
|
Emergency Medical Services | 2 | 2019 | 1947 | 0.090 |
Why?
|
Liver Cirrhosis | 1 | 2020 | 1960 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2020 | 2781 | 0.080 |
Why?
|
Follow-Up Studies | 6 | 2022 | 39345 | 0.080 |
Why?
|
Thrombectomy | 2 | 2023 | 676 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 4114 | 0.070 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2019 | 2816 | 0.070 |
Why?
|
Hypoglycemic Agents | 1 | 2020 | 3108 | 0.070 |
Why?
|
Prognosis | 4 | 2019 | 29979 | 0.070 |
Why?
|
Sex Characteristics | 1 | 2017 | 2650 | 0.070 |
Why?
|
Cross-Over Studies | 2 | 2023 | 2107 | 0.060 |
Why?
|
Time Factors | 6 | 2024 | 40214 | 0.060 |
Why?
|
Severity of Illness Index | 2 | 2024 | 15944 | 0.050 |
Why?
|
Norway | 1 | 2024 | 500 | 0.050 |
Why?
|
Recurrence | 3 | 2021 | 8507 | 0.050 |
Why?
|
Factor Xa | 1 | 2024 | 165 | 0.050 |
Why?
|
Retrospective Studies | 8 | 2024 | 81746 | 0.050 |
Why?
|
Brain | 2 | 2019 | 27366 | 0.050 |
Why?
|
Heart Valves | 1 | 2023 | 284 | 0.050 |
Why?
|
Phenprocoumon | 1 | 2021 | 19 | 0.050 |
Why?
|
Acenocoumarol | 1 | 2021 | 18 | 0.050 |
Why?
|
Pleura | 1 | 2023 | 245 | 0.050 |
Why?
|
Leukocytosis | 1 | 2022 | 251 | 0.050 |
Why?
|
Risk Assessment | 4 | 2024 | 24314 | 0.040 |
Why?
|
Multiple Myeloma | 1 | 2017 | 5196 | 0.040 |
Why?
|
Disease Progression | 1 | 2016 | 13665 | 0.040 |
Why?
|
Cerebral Angiography | 1 | 2024 | 1264 | 0.040 |
Why?
|
Germany | 1 | 2021 | 883 | 0.040 |
Why?
|
Denmark | 1 | 2021 | 776 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13499 | 0.040 |
Why?
|
Administration, Intravesical | 1 | 2018 | 88 | 0.040 |
Why?
|
Intubation, Gastrointestinal | 1 | 2019 | 166 | 0.040 |
Why?
|
Magnetic Resonance Angiography | 1 | 2024 | 1429 | 0.040 |
Why?
|
Deglutition | 1 | 2019 | 208 | 0.040 |
Why?
|
Thrombocytosis | 1 | 2018 | 88 | 0.040 |
Why?
|
Atrophy | 1 | 2022 | 1646 | 0.040 |
Why?
|
Chromogenic Compounds | 1 | 2017 | 29 | 0.040 |
Why?
|
Adult | 8 | 2024 | 223583 | 0.030 |
Why?
|
Prevalence | 2 | 2024 | 15867 | 0.030 |
Why?
|
Gastrostomy | 1 | 2019 | 325 | 0.030 |
Why?
|
Heparin | 1 | 2023 | 1636 | 0.030 |
Why?
|
Platelet Count | 1 | 2018 | 787 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2021 | 857 | 0.030 |
Why?
|
Patient Admission | 1 | 2022 | 1365 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 4 | 2024 | 36742 | 0.030 |
Why?
|
Child, Preschool | 1 | 2016 | 42665 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4857 | 0.030 |
Why?
|
Warfarin | 1 | 2021 | 1493 | 0.030 |
Why?
|
Sex Factors | 1 | 2024 | 10627 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2020 | 2336 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 26375 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9609 | 0.020 |
Why?
|
Acute Disease | 1 | 2019 | 7241 | 0.020 |
Why?
|
Patient Discharge | 1 | 2022 | 3476 | 0.020 |
Why?
|
Hospitals | 1 | 2022 | 3886 | 0.020 |
Why?
|
Child | 1 | 2016 | 80906 | 0.020 |
Why?
|
Adolescent | 1 | 2016 | 89155 | 0.020 |
Why?
|
Chronic Disease | 1 | 2021 | 9384 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 22287 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 4055 | 0.020 |
Why?
|
Blood Pressure | 1 | 2021 | 8540 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5314 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2023 | 20218 | 0.020 |
Why?
|
Survival Rate | 1 | 2019 | 12828 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10098 | 0.020 |
Why?
|
Electrocardiography | 1 | 2016 | 6411 | 0.010 |
Why?
|
Age Factors | 1 | 2019 | 18407 | 0.010 |
Why?
|
Incidence | 1 | 2019 | 21532 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8748 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20757 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 12252 | 0.010 |
Why?
|
United States | 1 | 2022 | 73027 | 0.010 |
Why?
|